Medical research helps shape the future of eye care — but historically, not all communities have been equally represented in clinical trials.
This matters because some eye diseases, including glaucoma and diabetic eye disease, can affect certain populations differently. Without diverse participation in research, treatments may not fully reflect the needs of all patients.
That’s one reason Wagner Kapoor Institute proudly participates in the Advancing Inclusive Research (AIR) Site Alliance, a national initiative focused on improving diversity and accessibility in ophthalmology clinical research.
This effort helps:
- Increase access to clinical trials
- Provide multilingual patient education
- Reduce barriers to participation
- Improve representation in ophthalmology research
At Wagner Kapoor Institute, we believe better research leads to better care — for every patient and every community.
If you’re interested in learning more about clinical research opportunities, call our research team at 757-271-3346.
Author
Alan L. Wagner, MD, FACS, FICS, FASRS, AME
Dr. Alan Wagner is recognized internationally as an innovator in the treatment of patients with retinal and macula disease, diabetic retinopathy, retinal detachments, ocular oncology, and the application of Lean Six Sigma to healthcare delivery.
Dr. Wagner is engaged in setting and advocating healthcare policy, currently serving as Chair of the American College of Surgeons’ Advisory Council for Ophthalmic Surgery and in the past positions including President of the Virginia Society of Eye Physicians and Surgeons, Secretariat of State Affairs and Counselor for the American Academy of Ophthalmology, President of the Medical Society of Virginia Foundation, Board of Visitors as well as Trustee at Eastern Virginia Medical School, President of the Virginia Beach Medical Society, and appointed by five Virginia Governors to multiple Commissions and Board positions.
Dr. Wagner’s integrated team approach enables the latest in diagnosis, treatment, and leading-edge research.
